|Bid||0.00 x 800|
|Ask||0.00 x 1300|
|Day's Range||20.04 - 25.79|
|52 Week Range||9.24 - 29.40|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.60|
Subscribe to Yahoo Finance Plus to view Fair Value for RANILearn more
Seventy-two Bay Area companies have gone public this year. But only 29 have increased in value since their debut.
A game-changing pill from Rani Therapeutics may offer an easier alternative to fight debilitating diseases.
SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 9:00 a.m. PT / 12:00 p.m. ET. Interested parties can access the live audio webcast for this conference from the Events page in the Investor Relat